Artwork

Content provided by BMJ talk medicine and BMJ Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BMJ talk medicine and BMJ Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Biomarker reduction indicates treatment response to Belimumab

14:36
 
Share
 

Manage episode 363969121 series 1426075
Content provided by BMJ talk medicine and BMJ Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BMJ talk medicine and BMJ Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Dr. Anna Wolska from the Lupus Foundation of America interviews Dr. Andrea Fava from Johns Hopkins University about Belimumab treatment in lupus nephritis. Dr Fava elucidates on the correlation between the decrease in urinary CD163 levels and the response to Belimumab treatment in Lupus Nephritis trials. The conversation provides important insights into the efficacy of this treatment option and potential biomarker use for personalized and precision medicine in the future. Read the article: http://dx.doi.org/10.1136/lupus-2022-000763
  continue reading

4250 episodes

Artwork
iconShare
 
Manage episode 363969121 series 1426075
Content provided by BMJ talk medicine and BMJ Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BMJ talk medicine and BMJ Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Dr. Anna Wolska from the Lupus Foundation of America interviews Dr. Andrea Fava from Johns Hopkins University about Belimumab treatment in lupus nephritis. Dr Fava elucidates on the correlation between the decrease in urinary CD163 levels and the response to Belimumab treatment in Lupus Nephritis trials. The conversation provides important insights into the efficacy of this treatment option and potential biomarker use for personalized and precision medicine in the future. Read the article: http://dx.doi.org/10.1136/lupus-2022-000763
  continue reading

4250 episodes

Wszystkie odcinki

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide